Welcome to our dedicated page for NYSE news (Ticker: NYSE), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYSE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYSE's position in the market.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.
Actinium Pharmaceuticals (NYSE: ATNM) provided a corporate update on September 21, 2022, highlighting key upcoming milestones in its clinical pipeline. Key data releases expected include topline results from the pivotal Phase 3 SIERRA trial for Iomab-B and overall survival data from the Actimab-A CLAG-M combination trial, both anticipated in Q4 2022. The company reported approximately $116 million in cash and equivalents as of Q2 2022, sufficient to support operations through mid-2025, facilitating its commitment to advancing targeted radiotherapies for patients with high unmet medical needs.
Volta Inc. (NYSE: VLTA) is set to release its first quarter 2022 results on Friday, May 13, 2022, before market open. This announcement will be followed by a conference call at 8:00 a.m. Eastern Time. Investors can listen to the call through the Investor Relations section of Volta's website or via telephone. A replay of the call will be available approximately three hours after it concludes, lasting until May 27, 2022. Volta is a leading provider of commerce-centric EV charging networks, aiming to support the transition to electric mobility.
Summary not available.
Horace Mann Educators Corporation (NYSE:HMN) will release its fourth-quarter and full-year 2021 results on February 1, after market close. A conference call to discuss these results is scheduled for February 2 at 10 a.m. ET. The financial information will be available on the company’s investor website. Founded in 1945, Horace Mann is dedicated to providing financial services tailored for educators, emphasizing its mission to help them achieve lifelong financial success.
Rockley Photonics (NYSE: RKLY) has signed partnership agreements with five top global consumer electronics manufacturers to enhance its non-invasive VitalSpex™ biomarker sensing platform. These collaborations will enable the integration of advanced biomarker measurements into consumer devices like smartwatches and wristbands, expanding Rockley's market presence. The platform aims to deliver real-time health insights by measuring various biomarkers including body temperature, blood pressure, and glucose trends. Rockley is conducting human studies to refine its sensing technology.
CCC Intelligent Solutions has successfully refinanced its secured credit facility, establishing an $800 million senior secured term loan and a $250 million senior secured revolving credit facility. This strategic move aims to bolster the company's balance sheet, with a reported 50% reduction in net leverage and $20 million in decreased projected annual cash interest payments. The term loan has a maturity date of September 21, 2028, while the revolving facility matures on September 21, 2026. The refinancing aims to support growth initiatives and enhance value for customers and shareholders.
Stem, Inc. (NYSE: STEM) has entered a memorandum of understanding with CleanCapital for a new financing partnership aimed at enhancing clean energy storage solutions. This collaboration will establish Stem as CleanCapital's preferred energy storage provider, focusing on mid-market commercial energy storage and small utility projects up to 30 MW across the U.S. CleanCapital, backed by a $300 million investment from Manulife Investment Management, aims to expand its clean energy portfolio. The partnership is expected to drive significant investments in energy storage and solar projects.
Puxin Limited (NYSE: NEW) reported its Q1 2021 financial results, showing a net revenue decline of 8.6% to RMB686.8 million (US$104.8 million) compared to Q1 2020. However, operating income rose 78.9% to RMB6.5 million (US$1.0 million). The company transitioned some learning centers online due to pandemic measures, contributing to a 7.1% drop in student enrollments to 539,355. Despite challenges, net income improved to RMB37.8 million (US$5.8 million), a positive shift from a net loss of RMB43.5 million in Q1 2020. Puxin anticipates Q2 revenues between RMB661.2 million and RMB691.3 million.